$5.42
0.55% yesterday
Nasdaq, Aug 21, 10:00 pm CET
ISIN
NL0015436031
Symbol
CVAC

CureVac N.V. Stock price

$5.42
+0.02 0.37% 1M
+2.12 64.24% 6M
+2.01 58.94% YTD
+2.10 63.25% 1Y
-5.87 51.99% 3Y
-61.78 91.93% 5Y
-50.48 90.30% 10Y
-50.48 90.30% 20Y
Nasdaq, Closing price Thu, Aug 21 2025
-0.03 0.55%
ISIN
NL0015436031
Symbol
CVAC
Industry

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$750.6m
Net debt
positive
Cash
$513.2m
Shares outstanding
225.2m
Valuation (TTM | estimate)
P/E
5.8 | negative
P/S
2.0 | 14.9
EV/Sales
1.2 | 9.2
EV/FCF
4.5
P/B
1.6
Financial Health
Equity Ratio
86.8%
Return on Equity
23.3%
ROCE
28.8%
ROIC
69.5%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$607.9m | $81.7m
EBITDA
$251.3m | $-118.0m
EBIT
$227.8m | $-146.0m
Net Income
$209.7m | $-125.7m
Free Cash Flow
$166.2m
Growth (TTM | estimate)
Revenue
787.6% | -86.8%
EBITDA
180.2% | -151.6%
EBIT
167.3% | -170.8%
Net Income
166.1% | -166.8%
Free Cash Flow
145.9%
Margin (TTM | estimate)
Gross
87.6%
EBITDA
41.3% | -144.4%
EBIT
37.5%
Net
34.5% | -153.8%
Free Cash Flow
27.3%
More
EPS
$0.9
FCF per Share
$0.7
Short interest
0.7%
Employees
904
Rev per Employee
$690.0k
Show more

Is CureVac N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

CureVac N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a CureVac N.V. forecast:

6x Buy
46%
7x Hold
54%

Analyst Opinions

13 Analysts have issued a CureVac N.V. forecast:

Buy
46%
Hold
54%

Financial data from CureVac N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
608 608
788% 788%
100%
- Direct Costs 75 75
55% 55%
12%
532 532
631% 631%
88%
- Selling and Administrative Expenses 74 74
19% 19%
12%
- Research and Development Expense 174 174
36% 36%
29%
251 251
180% 180%
41%
- Depreciation and Amortization 23 23
7% 7%
4%
EBIT (Operating Income) EBIT 228 228
167% 167%
37%
Net Profit 210 210
166% 166%
34%

In millions USD.

Don't miss a Thing! We will send you all news about CureVac N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CureVac N.V. Stock News

Neutral
Accesswire
7 days ago
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all shares of CureVac, uniting two highly complementary German companies to bring transformative mRNA-based treatments to patients globally Entered into agreements to resolve and dismiss all pen...
More CureVac N.V. News

Company Profile

CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Head office Netherlands
CEO Alexander Zehnder
Employees 904
Founded 2020
Website www.curevac.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today